Published on: May 25, 2026

PRISM BioLab today announced that the abstract titled “Leveraging E7386 phase 1 trials for cardiac safety: gaining concentration-QTc insights to inform early-stage oncology development” is now available. E7386 is a molecule jointly created by PRISM BioLab and Eisai Co., Ltd. The results will be published as an ASCO Online Publication by Eisai at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, to be held in Chicago, Illinois, USA, from May 29 to June 2, 2026.

For more details, please click here.